Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Adrenocortical Carcinoma Pipeline Drugs Market

Adrenal cortex cancer (ACC) symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in the chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females, and deepened voice in females. The Adrenocortical Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) and features dormant and discontinued projects.

Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 4, Mast/Stem Cell Growth Factor Receptor Kit, roto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, and Vascular Endothelial Growth Factor Receptor 2.

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Targets

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Targets

For more Adrenocortical Carcinoma pipeline drugs market target insights, download a free report sample

Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanism of actions of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor.

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Mechanism of Actions

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample

Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Adrenocortical Carcinoma pipeline drugs market are intravenous, oral, intraperitoneal, intrathecal, subcutaneous, intracerebral, intravesical, and parenteral.

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Routes of Administration

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample

Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Adrenocortical Carcinoma pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, and vaccine.

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Molecule Types

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Adrenocortical Carcinoma pipeline drugs market are GSK plc, Merck & Co Inc, Pharma Mar SA, Bristol-Myers Squibb Co, Corcept Therapeutics Inc, Eisai Co Ltd, Enterome Bioscience SA, Exelixis Inc, Fusion Pharmaceuticals Inc, and Infinity Pharmaceuticals Inc.

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Companies

Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Companies

To know more about the Adrenocortical Carcinoma pipeline drugs market companies, download a free report sample

Adrenocortical Carcinoma Pipeline Drugs Market Report Overview

Key Targets Programmed Cell Death Protein 1, Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 4, Mast/Stem Cell Growth Factor Receptor Kit, roto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, and Vascular Endothelial Growth Factor Receptor 2
Key Mechanism of Actions Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor
Key Routes of Administration Intravenous, Oral, Intraperitoneal, Intrathecal, Subcutaneous, Intracerebral, Intravesical, and Parenteral
Key Molecule Types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Oncolytic Virus, and Vaccine
Leading Companies GSK plc, Merck & Co Inc, Pharma Mar SA, Bristol-Myers Squibb Co, Corcept Therapeutics Inc, Eisai Co Ltd, Enterome Bioscience SA, Exelixis Inc, Fusion Pharmaceuticals Inc, and Infinity Pharmaceuticals Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • Reviews of pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Bristol-Myers Squibb Co
Corcept Therapeutics Inc
Eisai Co Ltd
Enterome Bioscience SA
Exelixis Inc
Fusion Pharmaceuticals Inc
GSK plc
Infinity Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
Orphagen Pharmaceuticals Inc
Pharma Mar SA
Sanofi
Seneca Therapeutics Inc
Tempest Therapeutics Inc
Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Overview

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Corcept Therapeutics Inc

Eisai Co Ltd

Enterome Bioscience SA

Exelixis Inc

Fusion Pharmaceuticals Inc

GSK plc

Infinity Pharmaceuticals Inc

Merck & Co Inc

Merck KGaA

Orphagen Pharmaceuticals Inc

Pharma Mar SA

Sanofi

Seneca Therapeutics Inc

Tempest Therapeutics Inc

Y-mAbs Therapeutics Inc

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drug Profiles

8H-9 – Drug Profile

Product Description

Mechanism Of Action

avelumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

cabazitaxel – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cabometyx – Drug Profile

Product Description

Mechanism Of Action

History of Events

derazantinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

dostarlimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

ecubectedin – Drug Profile

Product Description

Mechanism Of Action

History of Events

eganelisib – Drug Profile

Product Description

Mechanism Of Action

History of Events

EO-2401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

FPI-1434 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ipilimumab + nivolumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

lenvatinib mesylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

nevanimibe hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

niraparib – Drug Profile

Product Description

Mechanism Of Action

History of Events

omburtamab – Drug Profile

Product Description

Mechanism Of Action

History of Events

OR-449 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pembrolizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

relacorilant – Drug Profile

Product Description

Mechanism Of Action

History of Events

SVV-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Product Development Milestones

Featured News & Press Releases

Jun 14, 2022: Orphagen Pharmaceuticals presents data on downstream targets of SF-1 Antagonist OR-449 at ENDO 2022

Jun 04, 2018: Infinity Reports IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study at American Society of Clinical Oncology Annual Meeting

Jan 08, 2018: Infinity Provides Update on IPI-549 Phase I/Ib Study, 2018 Goals and Financial Guidance

Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting

Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome

Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016

Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015

Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers

Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Bristol-Myers Squibb Co, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Corcept Therapeutics Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Eisai Co Ltd, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Enterome Bioscience SA, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Exelixis Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Fusion Pharmaceuticals Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by GSK plc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Infinity Pharmaceuticals Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Merck & Co Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Merck KGaA, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Orphagen Pharmaceuticals Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Pharma Mar SA, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Sanofi, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Seneca Therapeutics Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Tempest Therapeutics Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Y-mAbs Therapeutics Inc, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects, 2022

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.